Advertisement

Annals of Hematology

, Volume 98, Issue 8, pp 1919–1925 | Cite as

Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice

  • Emilia Scalzulli
  • Matteo Molica
  • Danilo Alunni Fegatelli
  • Gioia Colafigli
  • Lorenzo Rizzo
  • Marco Mancini
  • Fabio Efficace
  • Roberto Latagliata
  • Robin Foà
  • Massimo BrecciaEmail author
Original Article
  • 105 Downloads

Abstract

The outcome of high-risk myelodysplastic syndrome (MDS) patients treated with 5-azacitidine (5-AZA) in the real-life setting remains largely unknown. We evaluated 110 MDS patients (IPSS intermediate 2/high) treated outside of clinical trials at a single institution between September 2003 and January 2017. Median duration of therapy was 9.5 cycles. The overall survival (OS) of the whole cohort was 66.1% at 1 year and 38.3% at 2 years. No differences in terms of OS were observed with regard to gender (p = 0.622) and age at baseline (< 65 years, 65–75, and > 75 years, p = 0.075). According to the IPSS-R, the very high-risk group had an inferior 2-year OS (17%) compared with intermediate-group patients (64%, p < 0.001). Transfusion independency at baseline was identified as a favorable prognostic factor on 1-year (66.8%) and 2-year OS (43.4%) (p < 0.001). After four cycles, the persistence of bone marrow blasts > 10% identified patients with a worse outcome, with a 2-year OS of 9.4% (p = 0.002). The occurrence of an infection during the first four cycles impacted on the 2-year OS (31.6% vs 58.3% in patients without infections, p = 0.032). Patients receiving at least 24 cycles of the drug have a 5-year OS of 38.2%. This analysis allowed to identify features at baseline or during treatment with 5-AZA associated with a different 2-year OS.

Keywords

Azacitidine Hypomethylating agent Myelodysplastic syndromes Real-life 

Notes

Authors’ contributions

MB designed the study and wrote and revised the manuscript; ES wrote the manuscript; MM collected the data; DAF and FE analyzed the data; LR, RL, GC, and MMa followed the patients; RF critically revised the paper and approved the final version.

Compliance with ethical standards

Conflict of interest

MB received honoraria by Novartis, Pfizer, and Incyte; FE received personal fees from Bristol Myers Squibb, Incyte, Orsenyx, and Amgen. All other authors declare no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

277_2019_3724_MOESM1_ESM.docx (693 kb)
ESM 1 (DOCX 692 kb)

References

  1. 1.
    Tefferi A, Vardiman JW (2009) Myelodysplastic syndromes. N Engl J Med 361:1872–1885CrossRefGoogle Scholar
  2. 2.
    Montalban-Bravo G, Garcia-Manero G (2018) Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management. Am J Hematol 93:129–147CrossRefGoogle Scholar
  3. 3.
    Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088Google Scholar
  4. 4.
    Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SMM, Miyazaki Y, Pfeilstocker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120(12):2454–2465CrossRefGoogle Scholar
  5. 5.
    Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C, Cazzola M (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution inmyelodysplastic syndromes. J Clin Oncol 25(23):3503–3510CrossRefGoogle Scholar
  6. 6.
    Silvermann LR (2004) DNA methyltransferase inhibitors in myelodysplastic syndrome. Best Pract Res Clin Haematol 17(4):585–594CrossRefGoogle Scholar
  7. 7.
    Aimiuwu J, Wang H, Chen P, Xie Z, Wang J, Liu S, Klisovic R, Mims A, Blum W, Marcucci G, Chan KK (2012 31) RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. Blood. 119(22):5229–5238CrossRefGoogle Scholar
  8. 8.
    Beguin Y, Selleslag D, Meers S, Graux C, Bries G, Deeren D, Vrelust I, Ravoet C, Theunissen K, Voelter V, Potier H, Trullemans F, Noens L, Mineur P (2015) Safety and efficacy of azacytidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey. Acta Clin Belg 70(1):34–43CrossRefGoogle Scholar
  9. 9.
    Voso MT, Niscola P, Piciocchi A et al (2016) Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. Eur J Haematol 96(4):344–351CrossRefGoogle Scholar
  10. 10.
    Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR, International Vidaza High-Risk MDS Survival Study Group (2009) International Vidaza High-Risk MDS Survival Study Group Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10(3):223–232CrossRefGoogle Scholar
  11. 11.
    Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405CrossRefGoogle Scholar
  12. 12.
    Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Löwenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL, World Health Organization(WHO) international working group (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 96:3671–3674Google Scholar
  13. 13.
    Itzykson R, Thepot S, Quesnel B (2011) Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 117(2):403–411CrossRefGoogle Scholar
  14. 14.
    Bernal T, Martínez-Camblor P, Sánchez-García J et al (2015) Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. Leukemia 29(9):1875–1881CrossRefGoogle Scholar
  15. 15.
    Mozessohn L, Cheung MC, Fallahpour S, Gill T, Maloul A, Zhang L, Lau O, Buckstein R (2018) Azacitidine in the ‘real-world’: an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada. Br J Haematol 181(6):803–815CrossRefGoogle Scholar
  16. 16.
    Zeidan AM, Davidoff AJ, Long JB, Hu X, Wang R, Ma X, Gross CP, Abel GA, Huntington SF, Podoltsev NA, Hajime U, Prebet T, Gore SD (2016) Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. Br J Haematol 175:829–840CrossRefGoogle Scholar
  17. 17.
    Molteni A, Riva M, Borin L, Bernardi M, Pelizzari AM, Freyrie A, Porta MD, Nichelatti M, Ravano E, Quaresmini G, Mariotti J, Caramazza D, Ubezio M, Guarco S, Gigli F, Greco R, Cairoli R, Morra E (2016) The influence of disease and comorbidity risk assessment on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: a retrospective analysis in ten centers of the “Rete Ematologica Lombarda”. Leuk Res 42:21–27CrossRefGoogle Scholar
  18. 18.
    Schuck A, Goette MC, Neukirchen J, Kuendgen A, Gattermann N, Schroeder T, Kobbe G, Germing U, Haas R (2017) A retrospective study evaluating the impact of infectious complications during azacitidine treatment. Ann Hematol 96:1097–1104CrossRefGoogle Scholar
  19. 19.
    Merkel D, Filanovsky K, Gafter-Gvili A, Vidal L, Aviv A, Gatt ME, Silbershatz I, Herishanu Y, Arad A, Tadmor T, Dally N, Nemets A, Rouvio O, Ronson A, Herzog-Tzarfati K, Akria L, Braester A, Hellmann I, Yeganeh S, Nagler A, Leiba R, Mittelman M, Ofran Y (2013) Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicentre study. Am J Hematol 88:130–134CrossRefGoogle Scholar
  20. 20.
    Kuendgen A, Muller-Thomas C, Lauseker M et al (2018) Efficacy of azacitidine is independent of molecular and clinical characteristics-an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature. Oncotarget 9:27882–22789CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Emilia Scalzulli
    • 1
  • Matteo Molica
    • 1
  • Danilo Alunni Fegatelli
    • 2
  • Gioia Colafigli
    • 1
  • Lorenzo Rizzo
    • 1
  • Marco Mancini
    • 1
  • Fabio Efficace
    • 3
  • Roberto Latagliata
    • 1
  • Robin Foà
    • 1
  • Massimo Breccia
    • 1
    Email author
  1. 1.Hematology, Department of Precision and Translational Medicine, Azienda Ospedaliera Policlinico Umberto ISapienza UniversityRomeItaly
  2. 2.Department of Statistical SciencesSapienza UniversityRomeItaly
  3. 3.Data Center and Health Outcomes Research UnitItalian Group for Adult Hematologic Diseases (GIMEMA)RomeItaly

Personalised recommendations